Xenon Pharmaceuticals

Beskrivning

Land	Kanada
Lista	77
Sektor	Hälsovård
Industri	Bioteknik

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Filter

År

Typ

Språk

Rensa

2026-08-28 22:01:00 Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 59,99 USD | -3,13%

2026-08-26 22:01:00 Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026 63,79 USD | +5,58%

2026-08-06 22:01:00 Xenon Reports Q2 2026 Financial Results and Provides Business Update 64,55 USD | +0,39%

2026-07-31 22:01:00 Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 62,67 USD | -2,37%

2026-07-30 22:01:00 Xenon to Report Q2 2026 Financial Results on August 6, 2026 64,19 USD | +1,73%

2026-07-02 22:01:00 Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 60,96 USD | +1,09%

2026-05-29 22:01:00 Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 54,73 USD | -0,11%

2026-05-07 22:01:00 Xenon Reports Q1 2026 Financial Results and Provides Business Update 56,00 USD | -4,42%

2026-05-01 22:01:00 Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 56,13 USD | +0,16%

2026-04-30 22:01:00 Xenon to Report Q1 2026 Financial Results on May 7, 2026 56,04 USD | +0,52%

2026-04-20 00:00:00 Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting 57,09 USD | -4,37%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode